180 LIFE SCIENCES CORP (ATNF)
US68236V3024 - Common Stock
Overall ATNF gets a fundamental rating of 2 out of 10. We evaluated ATNF against 565 industry peers in the Biotechnology industry. ATNF may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ATNF is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ATNF had negative earnings in the past year.
ATNF had a negative operating cash flow in the past year.
ATNF had negative earnings in each of the past 5 years.
In the past 5 years ATNF always reported negative operating cash flow.
1.2 Ratios
ATNF has a better Return On Assets (-29.82%) than 68.33% of its industry peers.
Looking at the Return On Equity, with a value of -83.61%, ATNF is in line with its industry, outperforming 50.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.82% | ||
| ROE | -83.61% | ||
| ROIC | N/A |
ROA(3y)-202.85%
ROA(5y)-126.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ATNF so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ATNF has been increased compared to 1 year ago.
The number of shares outstanding for ATNF has been increased compared to 5 years ago.
Compared to 1 year ago, ATNF has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -19.37, we must say that ATNF is in the distress zone and has some risk of bankruptcy.
ATNF has a Altman-Z score of -19.37. This is amonst the worse of the industry: ATNF underperforms 86.30% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ATNF is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, ATNF is in line with its industry, outperforming 47.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -19.37 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ATNF has a Current Ratio of 0.19. This is a bad value and indicates that ATNF is not financially healthy enough and could expect problems in meeting its short term obligations.
ATNF's Current ratio of 0.19 is on the low side compared to the rest of the industry. ATNF is outperformed by 97.15% of its industry peers.
A Quick Ratio of 0.19 indicates that ATNF may have some problems paying its short term obligations.
The Quick ratio of ATNF (0.19) is worse than 96.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.19 |
3. Growth
3.1 Past
ATNF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.18%, which is quite impressive.
EPS 1Y (TTM)98.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ATNF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.47% yearly.
The Revenue is expected to grow by 134.74% on average over the next years. This is a very strong growth
EPS Next Y50%
EPS Next 2Y22.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year481.87%
Revenue Next 2Y199.5%
Revenue Next 3Y177.22%
Revenue Next 5Y134.74%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ATNF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNF. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ATNF's earnings are expected to grow with 22.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.47%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ATNF does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
180 LIFE SCIENCES CORP
NASDAQ:ATNF (12/24/2024, 7:56:33 PM)
After market: 2.65 -0.25 (-8.62%)2.9
+1.03 (+55.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.69%
Inst Owner Change234.04%
Ins Owners1.05%
Ins Owner Change0%
Market Cap5.74M
Analysts82.86
Price TargetN/A
Short Float %3.43%
Short Ratio0.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.49
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.36
OCFYN/A
SpS0
BVpS1.89
TBVpS-2.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.82% | ||
| ROE | -83.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-202.85%
ROA(5y)-126.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.19 | ||
| Altman-Z | -19.37 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.52%
EPS Next Y50%
EPS Next 2Y22.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year481.87%
Revenue Next 2Y199.5%
Revenue Next 3Y177.22%
Revenue Next 5Y134.74%
EBIT growth 1Y63.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.09%
OCF growth 3YN/A
OCF growth 5YN/A